Overview
KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). While α-MSH is a 13-amino-acid neuropeptide with potent anti-inflammatory properties, research has identified that much of its anti-inflammatory activity resides in the KPV tripeptide fragment, which retains the parent molecule's ability to suppress inflammatory signaling without its melanogenic (tanning) or hormonal effects.
KPV has demonstrated remarkable anti-inflammatory efficacy in models of inflammatory bowel disease (IBD), particularly ulcerative colitis and Crohn's disease. Studies show that KPV can cross the intestinal epithelium, enter colonocytes, and directly suppress NF-κB-mediated inflammatory gene transcription. This ability to act locally within the gut while also modulating systemic inflammation makes KPV particularly attractive for GI-focused applications.
Unlike its parent molecule α-MSH, KPV does not bind to melanocortin receptors (MC1R-MC5R) with significant affinity, meaning it achieves its anti-inflammatory effects through receptor-independent mechanisms, primarily through direct nuclear translocation and NF-κB pathway inhibition. This non-receptor-mediated mechanism avoids the melanogenic, appetite, and hormonal side effects associated with melanocortin receptor agonists.
This guide reviews KPV's unique mechanism of action, preclinical evidence for IBD and inflammatory conditions, its favorable safety profile, and the practical considerations for this emerging anti-inflammatory peptide.
Quick facts
- Mechanism
- Alpha-MSH-derived tripeptide directly inhibiting NF-κB inflammation
- Primary use
- Anti-Inflammation & Gut Healing
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral, subcutaneous injection, topical, or intracolonic (research)
- Typical results
- Significant anti-inflammatory effects in colitis models; mucosal healing promotion
Chemical information
KPV (C₁₆H₃₁N₅O₄) is a anti-inflammatory compound with a molecular weight of 371.46 g/mol. Its structural characteristics underpin its biological activity in anti-inflammatory and immune modulation.
How KPV works
KPV exerts its anti-inflammatory effects primarily through direct entry into cells and translocation to the nucleus, where it inhibits the NF-κB signaling pathway—the master regulator of inflammatory gene expression. Unlike most anti-inflammatory peptides, KPV does not require cell surface receptor binding. Instead, it utilizes PepT1 (peptide transporter 1) on intestinal epithelial cells for cellular uptake, explaining its exceptional efficacy in gastrointestinal inflammation.
Once internalized, KPV interacts with the p65 subunit of NF-κB, preventing its nuclear translocation and DNA binding. This suppresses the transcription of a broad array of pro-inflammatory mediators including TNF-α, IL-1β, IL-6, IL-8, ICAM-1, and iNOS. The NF-κB pathway is hyperactivated in IBD, making this a particularly relevant therapeutic target. KPV's direct action on NF-κB is more targeted than corticosteroids, which broadly suppress immune function.
KPV also inhibits the production of pro-inflammatory prostaglandins by suppressing cyclooxygenase-2 (COX-2) expression, and reduces neutrophil migration to sites of inflammation by downregulating adhesion molecule expression. In colitis models, these combined effects translate to reduced mucosal inflammation, preserved epithelial barrier integrity, and accelerated mucosal healing.
An important advantage of KPV is its lack of immunosuppressive effects. While it potently reduces pathological inflammation, it does not impair the immune system's ability to fight infections or maintain surveillance against cancer—a significant limitation of many current IBD therapies (biologics, corticosteroids, thiopurines).
- NF-κB inhibition: Directly prevents NF-κB p65 nuclear translocation and inflammatory gene transcription
- PepT1 transport: Enters intestinal cells via peptide transporter 1 for direct intracellular action
- Cytokine suppression: Reduces TNF-α, IL-1β, IL-6, IL-8 without immunosuppression
- COX-2 inhibition: Suppresses prostaglandin synthesis and inflammatory pain signaling
- Barrier protection: Preserves intestinal epithelial tight junctions during inflammation
- Non-receptor mechanism: Does not activate melanocortin receptors; no melanogenic effects
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular weight | 371.46 g/mol | Very small tripeptide; excellent tissue penetration |
| PepT1 uptake | Active transport in gut | Efficient intestinal absorption via dedicated peptide transporter |
| Oral bioavailability | Good (PepT1-mediated) | Uniquely effective for oral administration among anti-inflammatory peptides |
| Half-life | Short (minutes, estimated) | Rapid degradation but sustained NF-κB inhibition |
| Stability (gastric) | Moderate | Small size and proline provide some protease resistance |
Dosing & administration
KPV dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for KPV is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Generally well-tolerated in preclinical studies
- • Mild GI discomfort (oral administration)
- • Injection site irritation (subcutaneous)
- • Minimal systemic effects reported
Serious / potential risks
- • No serious adverse events reported in published preclinical studies
- • No human clinical trial safety data available
- • Unknown long-term effects of chronic NF-κB modulation
- • Theoretical concern about impairing beneficial inflammatory responses
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| TNF-α inhibitors (infliximab, adalimumab) | Both suppress TNF-α; complementary but potentially redundant | May allow dose reduction of biologics; consult gastroenterologist |
| Corticosteroids | Both suppress NF-κB; additive anti-inflammatory effects | KPV may help facilitate steroid tapering in IBD |
| NSAIDs | NSAIDs can damage GI mucosa; KPV may be protective | Potentially protective combination; monitor for GI symptoms |
| BPC-157 | Complementary gut-healing mechanisms (BPC-157: mucosal repair; KPV: inflammation) | Commonly combined in gut-healing protocols |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $30–$60 per 5mg vial | Small tripeptide; relatively inexpensive to synthesize |
| Compounding pharmacies | $75–$150 per month | Custom capsules or solutions with prescription |
| Oral capsules (research) | $40–$80 per month | Enteric-coated for optimal gut delivery |
The bottom line
KPV is a compelling anti-inflammatory tripeptide that offers targeted NF-κB inhibition without immunosuppression or melanocortin receptor activation. Its ability to enter intestinal cells via PepT1 makes it particularly attractive for inflammatory bowel disease. While preclinical data is strong, human clinical trials are needed to validate its therapeutic potential.
Best for
- • Researchers studying gut inflammation and IBD mechanisms
- • Individuals with inflammatory GI conditions under medical supervision
- • Those seeking non-immunosuppressive anti-inflammatory approaches
- • Complementary gut-healing protocols with BPC-157
Not for
- • Replacement for established IBD therapies without medical guidance
- • Self-treatment of serious inflammatory conditions
- • Those expecting FDA-approved, validated therapy
- • Individuals with active infections requiring inflammatory responses
Related compounds
BPC-157
Gastric pentadecapeptide commonly combined with KPV for gut healing
LL-37
Antimicrobial peptide with complementary gut barrier protection
Glutathione
Master antioxidant supporting gut mucosal defense
Thymosin Alpha-1
Immune-modulating peptide for balanced immune function
Frequently asked questions
References
- [1] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al.. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). doi: 10.1053/j.gastro.2007.11.016 PMID: 18242207
- [2] Kannengiesser K, Maaser C, Heidemann J, et al.. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis (2008). doi: 10.1002/ibd.20334 PMID: 17985376
- [3] Brzoska T, Luger TA, Maaser C, et al.. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev (2008). doi: 10.1210/er.2007-0027 PMID: 18436707
- [4] Luger TA, Scholzen TE, Brzoska T, Böhm M.. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci (2003). doi: 10.1196/annals.1293.012 PMID: 14681143
- [5] Maaser C, Kannengiesser K, Specht C, et al.. Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut (2006). doi: 10.1136/gut.2005.083634 PMID: 16299033